| 產(chǎn)品名稱 | Daglutril - SLV 306 |
| 產(chǎn)品貨號 | Axon 1918 CAS [182821-27-8] MF C31H38N2O6MW 534.64 Purity: 99% Optical purity: Optically pure Soluble in DMSO Description An orally active, dual endothelin converting enzyme (ECE)/neutral endopeptidase (NEP) inhibitor that reduces proteinuria and urinary albumin excretion in diabetic rats. Simultaneous augmentation of ANP and inhibition of ET-1 production by Daglutril treatment is of potential therapeutic benefit in cardiovascular disease, and for treatment of overt nephropathy and reduction of albuminuria in hypertensive patients with type 2 diabetes. References Certificates Categories Extra info C. Th?ne-Reinke et al. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J. Cardiovasc. Pharmacol. 2004, 44, S76-79. ? K. Dickstein et al. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am. J. Cardiol. 2004, 94, 237-239.? ? R. Tabrizchi. SLV-306. Solvay. Curr. Opin. Investig. Drugs. 2003, 4, 329-332. Certificate of Analysis Material Safety Data Sheet Cardiovascular Cell Signaling & Oncology Pain & Inflammation ECE1 NEP EC 3.4.24 Orally active, dual ECE/NEP inhibitor Chemical name 2-((S)-3-(1-((R)-2-(ethoxycarbonyl)-4-phenylbutyl)cyclopentanecarboxamido)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid Parent CAS No. [182821-27-8] Order Size Unit Price Stock 2 mg €125.00 In Stock |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
Daglutril - SLV 306Axon 1918 CAS [182821-27-8] MF C31H38N2O6
Description
An orally active, dual endothelin converting enzyme (ECE)/neutral endopeptidase (NEP) inhibitor that reduces proteinuria and urinary albumin excretion in diabetic rats. Simultaneous augmentation of ANP and inhibition of ET-1 production by Daglutril treatment is of potential therapeutic benefit in cardiovascular disease, and for treatment of overt nephropathy and reduction of albuminuria in hypertensive patients with type 2 diabetes.
Orally active, dual ECE/NEP inhibitor
Chemical name2-((S)-3-(1-((R)-2-(ethoxycarbonyl)-4-phenylbutyl)cyclopentanecarboxamido)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid Parent CAS No.[182821-27-8] |
| 產(chǎn)品資料 |
